MEDICAL TECHNOLOGY
Untitled Page
If it’s in your blood, Irvine’s Masimo knows
The developer of innovative monitoring technologies releases the first-ever noninvasive hemoglobin monitor.
By Susan BelknappPublished: March 23, 2009 10:07 AM
Irvine-based Masimo, the inventor of multiple breakthrough health monitoring technologies, announced the full-market release of the first-ever noninvasive continuous hemoglobin monitor.
This revolutionary technology is the first of its kind to receive FDA 510(k) clearance for widespread commercial adoption. The monitor, Masimo SpHb, is already transforming the way hemoglobin testing is performed at more than 40 hospitals in the United States, Europe, Asia and Africa, where the technology’s limited market release was initiated in September 2008.
The availability of noninvasive, continuous and immediate hemoglobin measurements is expected to have a wide-ranging clinical impact, from surgery and intensive care t less acute care settings, including the emergency department, doctors’ offices, ambulatory surgery center and long-term care facility by facilitating prompt detection of internal bleeding and more appropriate administration of blood transfusions.
Early benefits of Masimo SpHb were evident in feedback received from clinicians at hospitals around the world who participated in the limited market release.
PAGE TWO
Related headlines
“OC METRO Minute,” March 24: DaVinci Biosciences – adult stem cell trial/spinal cord injury
Irvine’s Cortex Pharmaceuticals restructures, downsizes
“OC METRO Minute,” March 13: UCI’s geriatric program receives funding from Donald W. Reynolds Foundation
Studies show Irvine’s Cortex therapy slows memory loss
Irvine’s Spectrum Pharmaceuticals acquires RIT Oncology
San Clemente's STEMTech to Obama: What about adult stem cells?
|
||||
|
This revolutionary technology is the first of its kind to receive FDA 510(k) clearance for widespread commercial adoption. The monitor, Masimo SpHb, is already transforming the way hemoglobin testing is performed at more than 40 hospitals in the United States, Europe, Asia and Africa, where the technology’s limited market release was initiated in September 2008. The availability of noninvasive, continuous and immediate hemoglobin measurements is expected to have a wide-ranging clinical impact, from surgery and intensive care t less acute care settings, including the emergency department, doctors’ offices, ambulatory surgery center and long-term care facility by facilitating prompt detection of internal bleeding and more appropriate administration of blood transfusions. Early benefits of Masimo SpHb were evident in feedback received from clinicians at hospitals around the world who participated in the limited market release. PAGE TWO Related headlines “OC METRO Minute,” March 24: DaVinci Biosciences – adult stem cell trial/spinal cord injury Irvine’s Cortex Pharmaceuticals restructures, downsizes “OC METRO Minute,” March 13: UCI’s geriatric program receives funding from Donald W. Reynolds Foundation Studies show Irvine’s Cortex therapy slows memory loss Irvine’s Spectrum Pharmaceuticals acquires RIT Oncology San Clemente's STEMTech to Obama: What about adult stem cells? |
||||
